Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Philadelphia, Pennsylvania 19102


Recent evidence suggests multiple drug therapy is superior to single agents. The study compares the incidence of nausea, vomiting, need for rescue medication, prolonged PACU time, and unplanned hospital admission in patients with high risk for PONV treated with oral aprepitant with or without transdermal scopolamine preoperatively.

Study summary:

Postoperative nausea and vomiting (PONV) is a serious problem complicating surgery. PONV has an overall incidence of 30% and a 70% incidence in high-risk patients. PONV yields unplanned hospital admission, pulmonary aspiration, esophageal rupture, electrolyte abnormalities, dehydration, and delayed discharge from the postanesthesia care unit (PACU). Additional use of resources costs the health care industry hundreds of millions of dollars annually. Patient satisfaction is greatly improved when PONV is prevented.4 PONV etiology is multifactorial and the treatment is multimodal.


Inclusion Criteria: - Patient must be between 18 and 65 years of age. - Patient's ASA class must be between 1 and 3. - If patient is currently on oral contraceptive to prevent pregnancy, she must be willing to use a back up form of birth control for one month post study. - Patient must have 1 FACTOR to qualify - Female Sex - History of PONV - Motion Sickness - Non-Smoker - Intended Use of Post Operative Opioids Exclusion Criteria: - Patients with a history of vomiting due to middle ear infection, nervous system disorder, or any other condition. - The surgical procedure is less than 1 hour. - The patient is pregnant or breast feeding. - The patient has taken antiemetic medication in previous 24 hours. - Patients with narrow-angle glaucoma. - Allergy to belladonna alkaloids. - Hypersensitivity to barbiturates. - Patient taking any of the following medications: - Orap - Seldane - Hismanal - Propulsid - Phenytoin - Phenothiazines - Tricyclic Antidepressants - Meperidine - Tolbutamide - Aluminum and Magnesium Trisilicate-containing Antacids - Anti-Cholinergics - Coumadin - Male patients with prostate hypertrophy. - Patients with severe hepatic disease. - Patients on Chemotherapy and taking Aprepitant. - Patients with fever. - Patients with sepsis.



Primary Contact:

Study Director
Jay Horrow, MD
Drexel University College of Medicine

Backup Contact:


Location Contact:

Philadelphia, Pennsylvania 19102
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.